ROIV
Roivant Sciences Ltd.
$29.05
+1.97%
$20.5B
No data for this timeframe.
Vol
Market Cap$20.5B
Cap SizeLarge Cap
Analyst ConsensusStrong Buy (89%)
Insider Activity0B / 12S
Insider Net $-$119.6M
SEC Reports4
Press Releases3
Recent Activity
Sep 30, 2026
fda_pdufa
PDUFA: ROIV — brepocitinib in dermatomyositis — 2026-09-30
FDA target action date 2026-09-30 for ROIV (Roivant Sciences Ltd.). Drug: brepocitinib. Indication:
May 22, 2026
Insider
Venker Eric sold 200,000 shares
President & Immunovant CEO @ $3.85 ($770.0K)
May 22, 2026
Insider
Venker Eric sold 200,000 shares
President & Immunovant CEO @ $30.27 ($6.1M)
May 22, 2026
Insider
Venker Eric sold 200,000 shares
President & Immunovant CEO @ $0.00 ($0.00)
May 20, 2026
SEC
Roivant reported Q4 FY2026 non-GAAP loss per share of -$0.317, beating consensus of -$0.38, but revenue of $2.5M missed
8-K — Impact 6/10
May 20, 2026
SEC
Roivant Sciences reported Q4 FY2026 GAAP EPS of $0.43 (including a $770M litigation settlement gain) vs consensus of -$0
PRESS-RELEASE — Impact 7/10
Apr 21, 2026
SEC
Roivant reported preliminary cash of $4.3B as of March 31, 2026, and announced a new Phase 2b/3 trial for brepocitinib i
8-K — Impact 6/10
Apr 2, 2026
Press
Roivant announced a new Phase 2b/3 trial for brepocitinib in lichen planopilaris (LPP), a rare scarring hair loss condit
Impact 6/10
Price Targets
$39.04
+34.4% upside
Strong Buy
Current $29.05
Low $31.50
Median $40.00
High $45.00
12 analysts
$31.50
$45.00
Analyst Ratings
8Strong Buy
9Buy
2Hold
0Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| May 26, 2026 | Guggenheim | MAINTAIN | Buy → Buy |
| May 21, 2026 | Citigroup | MAINTAIN | Buy → Buy |
| May 21, 2026 | TD Cowen | MAINTAIN | Buy → Buy |
| May 21, 2026 | HC Wainwright & Co. | REITERATE | Buy → Buy |
| Apr 16, 2026 | Piper Sandler | MAINTAIN | Overweight → Overweight |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-0.36 ▼ -6.7% | $-0.47 — $-0.27 | -42% YoY | 3 |
| Next Q | $-0.40 ▼ -4.9% | $-0.55 — $-0.29 | -44% YoY | 3 |
| Current FY | $-1.50 ▼ -29.1% | $-1.96 — $-1.18 | -39% YoY | 3 |
| Next FY | $-1.56 ▼ -20.3% | $-1.91 — $-1.31 | -4% YoY | 3 |
Latest Reports
MIXED
8-K
6/10
Roivant reported Q4 FY2026 non-GAAP loss per share of -$0.317, beating consensus of -$0.38, but revenue of $2.5M missed
May 20, 2026
MIXED
PRESS-RELEASE
7/10
Roivant Sciences reported Q4 FY2026 GAAP EPS of $0.43 (including a $770M litigation settlement gain) vs consensus of -$0
May 20, 2026
MIXED
Press
6/10
Roivant announced a new Phase 2b/3 trial for brepocitinib in lichen planopilaris (LPP), a rare scarring hair loss condit
Apr 2, 2026
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| May 22, 2026 | Venker Eric | M | $770.0K |
| May 22, 2026 | Venker Eric | SELL | $6.1M |
| May 22, 2026 | Venker Eric | M | $0.00 |
| May 20, 2026 | Pulik Richard | F | $614.6K |
| May 20, 2026 | Venker Eric | F | $1.1M |
No institutional holding data available yet. Data is sourced from 13F filings which are filed quarterly.
12 unique insiders with 12 transactions. Net insider value: -$119.6M ($0.00 bought, $119.6M sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| May 22, 2026 | Venker Eric | President & Immunovant CEO | M | 200,000 | $3.85 | $770.0K |
| May 22, 2026 | Venker Eric | President & Immunovant CEO | SELL | 200,000 | $30.27 | $6.1M |
| May 22, 2026 | Venker Eric | President & Immunovant CEO | M | 200,000 | $0.00 | $0.00 |
| May 20, 2026 | Pulik Richard | CFO | F | 18,962 | $32.41 | $614.6K |
| May 20, 2026 | Venker Eric | President & Immunovant CEO | F | 34,483 | $32.41 | $1.1M |
| Apr 20, 2026 | Humes Jennifer | Chief Accounting Officer | A | 27,157 | $0.00 | $0.00 |
| Apr 20, 2026 | Pulik Richard | CFO | A | 60,644 | $0.00 | $0.00 |
| Apr 20, 2026 | Humes Jennifer | Chief Accounting Officer | A | 29,173 | $0.00 | $0.00 |
| Apr 20, 2026 | Pulik Richard | CFO | A | 84,026 | $0.00 | $0.00 |
| Apr 20, 2026 | Venker Eric | President & Immunovant CEO | M | 200,000 | $3.85 | $770.0K |
| Apr 20, 2026 | Venker Eric | President & Immunovant CEO | SELL | 200,000 | $29.59 | $5.9M |
| Apr 20, 2026 | Venker Eric | President & Immunovant CEO | M | 200,000 | $0.00 | $0.00 |
| Apr 17, 2026 | Epperly Melissa B, | Director | A | 670 | $0.00 | $0.00 |
| Apr 17, 2026 | MOMTAZEE JAMES C | Director | A | 469 | $0.00 | $0.00 |
| Apr 17, 2026 | MOMTAZEE JAMES C | Director | F | 94 | $29.83 | $2.8K |
| Apr 17, 2026 | Oren Ilan | Director | A | 896 | $0.00 | $0.00 |
| Apr 17, 2026 | Oren Ilan | Director | F | 95 | $29.83 | $2.8K |
| Apr 16, 2026 | Gline Matthew | CEO | SELL | 289,774 | $29.16 | $8.4M |
| Apr 8, 2026 | Humes Jennifer | Chief Accounting Officer | SELL | 13,538 | $28.37 | $384.1K |
| Mar 31, 2026 | Sukhatme Mayukh | President & CIO | F | 187,512 | $27.70 | $5.2M |
| Mar 31, 2026 | Gline Matthew | CEO | F | 304,684 | $27.70 | $8.4M |
| Mar 31, 2026 | Torti Frank | President and Vant Chair | F | 160,035 | $27.70 | $4.4M |
| Mar 30, 2026 | Sukhatme Mayukh | President & CIO | M | 58,391 | $0.00 | $0.00 |
| Mar 30, 2026 | Sukhatme Mayukh | President & CIO | F | 29,809 | $26.41 | $787.3K |
| Mar 30, 2026 | Gline Matthew | CEO | M | 97,319 | $0.00 | $0.00 |
| Mar 30, 2026 | Gline Matthew | CEO | F | 53,826 | $26.41 | $1.4M |
| Mar 30, 2026 | Sukhatme Mayukh | President & CIO | M | 1,306,889 | $11.50 | $15.0M |
| Mar 30, 2026 | Gline Matthew | CEO | M | 2,178,150 | $11.50 | $25.0M |
| Mar 26, 2026 | Fitzgerald Meghan | Director | M | 70,000 | $8.80 | $616.0K |
| Mar 26, 2026 | Fitzgerald Meghan | Director | SELL | 70,000 | $27.45 | $1.9M |
| Mar 26, 2026 | Fitzgerald Meghan | Director | M | 70,000 | $0.00 | $0.00 |
| Mar 20, 2026 | Humes Jennifer | Chief Accounting Officer | F | 14,526 | $27.70 | $402.4K |
| Mar 20, 2026 | Pulik Richard | CFO | F | 1,546 | $27.70 | $42.8K |
| Mar 17, 2026 | Venker Eric | President & Immunovant CEO | SELL | 200,000 | $28.24 | $5.6M |
| Mar 17, 2026 | Venker Eric | President & Immunovant CEO | M | 200,000 | $3.85 | $770.0K |
| Mar 17, 2026 | Venker Eric | President & Immunovant CEO | M | 200,000 | $0.00 | $0.00 |
| Mar 16, 2026 | Epperly Melissa B, | Director | SELL | 41,861 | $28.68 | $1.2M |
| Feb 23, 2026 | Torti Frank | President and Vant Chair | M | 587,390 | $3.85 | $2.3M |
| Feb 23, 2026 | Torti Frank | President and Vant Chair | SELL | 587,390 | $27.51 | $16.2M |
| Feb 23, 2026 | Torti Frank | President and Vant Chair | M | 587,390 | $0.00 | $0.00 |
| Feb 20, 2026 | Venker Eric | President & Immunovant CEO | F | 7,051 | $27.15 | $191.4K |
| Feb 20, 2026 | Pulik Richard | CFO | F | 1,000 | $27.15 | $27.1K |
| Feb 20, 2026 | Torti Frank | President and Vant Chair | M | 1,012,610 | $3.85 | $3.9M |
| Feb 20, 2026 | Torti Frank | President and Vant Chair | SELL | 1,012,610 | $27.15 | $27.5M |
| Feb 20, 2026 | Torti Frank | President and Vant Chair | M | 1,012,610 | $0.00 | $0.00 |
| Feb 19, 2026 | Torti Frank | President and Vant Chair | M | 1,400,000 | $3.85 | $5.4M |
| Feb 19, 2026 | Torti Frank | President and Vant Chair | SELL | 1,400,000 | $27.42 | $38.4M |
| Feb 19, 2026 | Torti Frank | President and Vant Chair | M | 1,400,000 | $0.00 | $0.00 |
| Feb 13, 2026 | MANCHESTER KEITH S | Director | SELL | 150,784 | $26.49 | $4.0M |
| Feb 13, 2026 | Gold Daniel Allen | Director | SELL | 150,784 | $26.49 | $4.0M |
4 SEC filing reports analyzed. Sentiment: 0 bullish, 0 bearish, 3 mixed, 1 neutral. Avg impact: 5.3/10.
MIXED
8-K
6/10
Roivant reported Q4 FY2026 non-GAAP loss per share of -$0.317, beating consensus of -$0.38, but reve
May 20, 2026
MIXED
PRESS-RELEASE
7/10
Roivant Sciences reported Q4 FY2026 GAAP EPS of $0.43 (including a $770M litigation settlement gain)
May 20, 2026
MIXED
8-K
6/10
Roivant reported preliminary cash of $4.3B as of March 31, 2026, and announced a new Phase 2b/3 tria
Apr 21, 2026
NEUTRAL
CLUSTER
2/10
Jennifer Humes, Chief Accounting Officer of Roivant Sciences Ltd., surrendered 14,526 shares to cove
Mar 24, 2026
MIXED
6/10
Roivant announced a new Phase 2b/3 trial for brepocitinib in lichen planopilaris (LPP), a rare scarr
Apr 2, 2026
BULLISH
7/10
Roivant Sciences' subsidiary Priovant has initiated a seamless Phase 2b/3 trial for brepocitinib in
Apr 2, 2026
BULLISH
8/10
Roivant Sciences subsidiary Priovant Therapeutics announced positive Phase 3 VALOR trial results for
Mar 28, 2026
Current analyst consensus: Strong Buy (89% buy). Based on 19 analysts: 8 strong buy, 9 buy, 2 hold, 0 sell, 0 strong sell.
Analyst Price Targets
$39.04 mean target
+34.4% upside
Strong Buy (1.31)
$31.50 Low
$45.00 High
| Metric | Value |
|---|---|
| Current Price | $29.05 |
| Target Low | $31.50 |
| Target Mean | $39.04 |
| Target Median | $40.00 |
| Target High | $45.00 |
| # Analysts | 12 |
| Recommendation | Strong Buy (1.31) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$-0.36 | $-0.47 | $-0.27 | -42.2% | -6.7% | 0↑ 2↓ | $0.0B | 9.3% | 3 |
| Next Q 2026-09-30 |
$-0.40 | $-0.55 | $-0.29 | -43.8% | -4.9% | 0↑ 3↓ | $0.0B | 154.2% | 3 |
| Current FY 2027-03-31 |
$-1.50 | $-1.96 | $-1.18 | -38.8% | -29.1% | 0↑ 3↓ | $0.1B | 844.0% | 3 |
| Next FY 2028-03-31 |
$-1.56 | $-1.91 | $-1.31 | -4.3% | -20.3% | 0↑ 3↓ | $0.5B | 525.5% | 3 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-0.356 | |
| 7d ago | $-0.333 | -0.022 |
| 30d ago | $-0.333 | -0.022 |
| 60d ago | $-0.290 | -0.066 |
| 90d ago | $-0.290 | -0.066 |
7 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 0 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| May 26, 2026 | Guggenheim | MAINTAIN | Buy | Buy |
| May 21, 2026 | Citigroup | MAINTAIN | Buy | Buy |
| May 21, 2026 | TD Cowen | MAINTAIN | Buy | Buy |
| May 21, 2026 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| Apr 16, 2026 | Piper Sandler | MAINTAIN | Overweight | Overweight |
| Mar 4, 2026 | HC Wainwright & Co. | MAINTAIN | Buy | Buy |
| Feb 10, 2026 | Citigroup | MAINTAIN | Buy | Buy |
| Feb 10, 2026 | HC Wainwright & Co. | MAINTAIN | Buy | Buy |
| Feb 9, 2026 | Guggenheim | MAINTAIN | Buy | Buy |
| Dec 15, 2025 | Leerink Partners | MAINTAIN | Outperform | Outperform |
| Dec 15, 2025 | Goldman Sachs | MAINTAIN | Buy | Buy |
| Dec 12, 2025 | HC Wainwright & Co. | MAINTAIN | Buy | Buy |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 8 | 9 | 2 | 0 | 0 | 89% | |
| May 1, 2026 | 8 | 9 | 2 | 0 | 0 | 89% | |
| Apr 1, 2026 | 8 | 9 | 2 | 0 | 0 | 89% | |
| Mar 1, 2026 | 7 | 9 | 2 | 0 | 0 | 89% | |
| Feb 1, 2026 | 7 | 9 | 2 | 0 | 0 | 89% | |
| Jan 1, 2026 | 7 | 9 | 2 | 0 | 0 | 89% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
Sep 30, 2026
fda_pdufa
PDUFA: ROIV — brepocitinib in dermatomyositis — 2026-09-30
FDA target action date 2026-09-30 for ROIV (Roivant Sciences Ltd.). Drug: brepocitinib. Indication: dermatomyositis. FDA assigned PDUFA target action
Jun 9, 2026
short_volume
Short Volume: ROIV — 64.0% short (0.6M / 1.0M)
Short: 637,960 | Exempt: 38 | TRF Vol: 996,651 | Short Ratio: 64.0% | Off-exchange volume (dark pool + OTC)
Jun 5, 2026
short_volume
Short Volume: ROIV — 60.3% short (0.9M / 1.4M)
Short: 855,205 | Exempt: 27,477 | TRF Vol: 1,418,805 | Short Ratio: 60.3% | Off-exchange volume (dark pool + OTC)
Jun 4, 2026
short_volume
Short Volume: ROIV — 57.6% short (0.6M / 1.0M)
Short: 602,380 | Exempt: 20,749 | TRF Vol: 1,046,205 | Short Ratio: 57.6% | Off-exchange volume (dark pool + OTC)
May 28, 2026
short_volume
Short Volume: ROIV — 59.6% short (0.7M / 1.3M)
Short: 745,832 | Exempt: 83,428 | TRF Vol: 1,251,784 | Short Ratio: 59.6% | Off-exchange volume (dark pool + OTC)
May 22, 2026
short_volume
Short Volume: ROIV — 60.7% short (1.2M / 2.0M)
Short: 1,225,839 | Exempt: 302,787 | TRF Vol: 2,019,377 | Short Ratio: 60.7% | Off-exchange volume (dark pool + OTC)
May 20, 2026
earnings
Roivant Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2026 and Provides Business Update
<p>BASEL, Switzerland and LONDON and NEW YORK, May 20, 2026 (GLOBE NEWSWIRE) -- Roivant (Nasdaq: ROIV) today reported its financial results for the
May 19, 2026
short_volume
Short Volume: ROIV — 55.5% short (0.6M / 1.2M)
Short: 644,582 | Exempt: 0 | TRF Vol: 1,160,705 | Short Ratio: 55.5% | Off-exchange volume (dark pool + OTC)
May 18, 2026
dark_pool
Dark Pool: ROIV — 9.8M shares, 118,301 trades
Week starting 2026-05-18. Total ATS volume: 9,806,786 shares across 118,301 trades.
May 13, 2026
short_volume
Short Volume: ROIV — 57.5% short (0.9M / 1.6M)
Short: 942,163 | Exempt: 0 | TRF Vol: 1,638,032 | Short Ratio: 57.5% | Off-exchange volume (dark pool + OTC)
May 12, 2026
short_volume
Short Volume: ROIV — 83.7% short (3.2M / 3.8M)
Short: 3,221,759 | Exempt: 27,126 | TRF Vol: 3,849,708 | Short Ratio: 83.7% | Off-exchange volume (dark pool + OTC)
May 11, 2026
dark_pool
Dark Pool: ROIV — 5.8M shares, 81,869 trades
Week starting 2026-05-11. Total ATS volume: 5,754,361 shares across 81,869 trades.
May 4, 2026
dark_pool
Dark Pool: ROIV — 3.8M shares, 59,193 trades
Week starting 2026-05-04. Total ATS volume: 3,760,607 shares across 59,193 trades.
Apr 27, 2026
dark_pool
Dark Pool: ROIV — 6.2M shares, 73,327 trades
Week starting 2026-04-27. Total ATS volume: 6,156,532 shares across 73,327 trades.
Apr 22, 2026
short_volume
Short Volume: ROIV — 83.7% short (4.1M / 4.9M)
Short: 4,132,657 | Exempt: 5,000 | TRF Vol: 4,939,377 | Short Ratio: 83.7% | Off-exchange volume (dark pool + OTC)